Company news

Dare Bioscience, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Daré Bioscience Announces Grant Award Supporting Development of Potential New Therapeutic Intervention for the Prevention of Idiopathic Preterm Birth

July 30, 2023

Daré Bioscience Announces Additional Positive Data from Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women

July 10, 2023

Daré Bioscience Announces Upcoming Webinar to Review Additional Data from Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder

July 5, 2023

Daré Bioscience Provides Update on Activities to Support Commercial Launch of XACIATO™ (clindamycin phosphate) vaginal gel, 2%, FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis

July 4, 2023

Daré Bioscience Announces Publication in Menopause: The Journal of The North American Menopause Society of Data from Phase 1/2 Open-Label Safety and Pharmacokinetics Study of DARE-HRT1 in Healthy Postmenopausal Women

June 20, 2023

Daré Bioscience Announces Publication of Phase 1/2 Pharmacokinetic, Safety and Pharmacodynamic Data for DARE-VVA1 - a Potential New Hormone-Free Treatment for Vulvovaginal Atrophy - in Climacteric, the Journal of the International Menopause Society

June 8, 2023

Daré Bioscience Announces Positive Topline Data from the Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder

June 4, 2023

Daré Bioscience to Participate in Two Upcoming Conferences: 2023 BIO International Convention and the Longwood Healthcare Leaders Spring 2023 MIT Conference

May 31, 2023

Daré Bioscience Announces Availability of Publication on the Patient-Centered Concept Elicitation Study for Female Sexual Arousal Disorder in The Journal of Sexual Medicine

May 30, 2023

Daré Bioscience Reports First Quarter 2023 Financial Results and Provides a Company Update

May 10, 2023

Daré Bioscience to Host First Quarter 2023 Financial Results and Company Update Conference Call and Webcast on May 11, 2023

May 3, 2023

Daré Bioscience Announces Initiation of Subject Enrollment in a Phase 1 Thermography Study to Support Pharmacodynamic and Pharmacokinetic Characterization of Sildenafil Cream, 3.6%

April 19, 2023

Daré Bioscience Announces Publication of Positive Safety and Acceptability Data from Phase 1 Clinical Trial that Support the Potential of DARE-HRT1 Intravaginal Ring as a New Menopausal Hormone Therapy

April 17, 2023

Daré Bioscience Reports Full Year 2022 Financial Results and Provides a Company Update

March 29, 2023

Daré Bioscience to Host Full-year 2022 Financial Results and Company Update Conference Call and Webcast on March 30, 2023

March 22, 2023

Daré Bioscience Announces Start of a Phase 1 Study for its Potential First-in-Category Treatment for Primary Dysmenorrhea, DARE-PDM1

February 21, 2023

Daré Bioscience Announces Publication in Menopause: The Journal of The North American Menopause Society of Data from Phase 1 Trial of DARE-HRT1 that Support the Potential of DARE-HRT1 as an Effective Hormone Therapy for both Vasomotor and Vaginal Symp...

January 25, 2023

Daré Bioscience Announces Positive Pharmacokinetic (PK) Results from the DARE-HRT1 Phase 1 / 2 Study that Support the Potential of DARE-HRT1 as an Effective Hormone Therapy for both Vasomotor and Vaginal Symptoms of Menopause

January 8, 2023

Daré Bioscience Announces New Development Program, DARE-PDM1, as a Potential First-in-Category Treatment for Primary Dysmenorrhea

December 11, 2022

Daré Bioscience Announces Grant to Develop Novel Hydrogel Formulation for Delivery of Live Biotherapeutics to Support Vaginal Health

November 14, 2022

Daré Bioscience Announces Positive Topline Results from DARE-VVA1 Phase 1/2 Clinical Study

November 13, 2022

Daré Bioscience Reports Third Quarter 2022 Financial Results and Provides a Company Update

November 9, 2022

Daré Bioscience Announces Subject Screening for Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder Complete

October 31, 2022

Daré Bioscience Announces Positive Efficacy Results from the DARE-HRT1 Phase 1 / 2 Study

October 16, 2022

Daré Bioscience Announces IDE Approval for a Single Arm, Open-Label Pivotal Contraceptive Efficacy Study of Ovaprene®, an Investigational Hormone-Free Monthly Intravaginal Contraceptive

October 9, 2022

Daré Bioscience Announces Interim Analysis of Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder

August 28, 2022

Daré Bioscience, Inc. Announces Global Licensing Rights to the Novel Antimicrobial Glycerol Monolaurate for Vaginal Health

August 23, 2022

Daré Bioscience Reports Second Quarter 2022 Financial Results and Provides a Company Update

August 8, 2022

Daré Bioscience to Host Second Quarter 2022 Financial Results and Company Update Conference Call and Webcast on August 9, 2022

August 1, 2022

Daré Bioscience Announces Closing of Global License Agreement with Organon to Commercialize XACIATO™ (clindamycin phosphate vaginal gel, 2%), FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis

June 29, 2022

Daré Bioscience Announces Partial Adjournment of Annual Meeting of Stockholders to July 14, 2022

June 23, 2022

Daré Bioscience to Participate in the 2022 BIO International Convention

June 5, 2022

Daré Bioscience Reports First Quarter 2022 Financial Results and Provides a Company Update

May 11, 2022

Daré Bioscience Announces NIH Grant Award

May 10, 2022

Daré Bioscience to Host First Quarter 2022 Financial Results and Company Update Conference Call and Webcast on May 12, 2022

May 4, 2022

Daré Bioscience Initiates Phase 1/2 Clinical Study of DARE-HRT1

April 11, 2022

Daré Bioscience Reports Full-Year 2021 Financial Results and Provides a Company Update

March 30, 2022

Daré Announces FDA Approval of XACIATO™ (clindamycin phosphate) Vaginal Gel as a Treatment for Bacterial Vaginosis

December 6, 2021

Daré Bioscience Reports Third Quarter 2021 Financial Results and Provides a Company Update

November 9, 2021

Daré Bioscience to Host Third Quarter 2021 Financial Results and Company Update Conference Call and Webcast on November 10, 2021

November 2, 2021

Daré Bioscience Announces NIH Grant Award to Support Development of DARE-LARC1

September 26, 2021

Daré Bioscience Initiates Phase 1/2 Clinical Study of DARE-VVA1, Intravaginal Tamoxifen for the Treatment of Vulvar and Vaginal Atrophy

September 22, 2021

Daré Bioscience Reports Second Quarter 2021 Financial Results and Provides a Company Update

August 11, 2021

Daré Bioscience Announces FDA Acceptance and Priority Review of New Drug Application for DARE-BV1 for the Treatment of Bacterial Vaginosis

August 8, 2021

Daré Bioscience to Host Second Quarter 2021 Financial Results and Company Update Conference Call and Webcast on August 12, 2021

August 4, 2021

Daré Announces Collaborative Research Agreement (CRADA) for the Pivotal Phase 3 Study of Ovaprene®, an Investigational Hormone-Free Monthly Contraceptive

July 11, 2021

Daré Bioscience Announces Positive Phase 1 Results for DARE-HRT1

June 27, 2021

Daré Bioscience Reports First Quarter 2021 Financial Results and Provides a Company Update

May 12, 2021

Daré Bioscience to Host First Quarter 2021 Financial Results and Company Update Conference Call and Webcast on May 13, 2021

May 5, 2021

Daré Bioscience Announces Ovaprene®, a Novel Investigational Hormone-Free Contraceptive, Poster Presentation at the 2021 Annual Clinical and Scientific Meeting of the American College of Obstetricians and Gynecologists

April 26, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 20 calls. Every call is listed under its year.

Decks

The 5 newest of 55 decks. Every deck is listed under its year.